Stay updated with breaking news from March Hedrick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline Funding for pediatric brain cancer treatment is expected to begin in Q3 2024, pending contract finalization
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’ scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (CNS) cancers Dr. Blouw is an expert in CNS tumor biology and in the diagnosis of neoplasms of the cerebrospinal fluid AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stag
The FDA has granted an orphan drug designation to rhenium obisbemeda as a potential therapeutic option for patients with breast cancer and leptomeningeal metastases.
03.11.2023 - AUSTIN, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) - Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ... Seite 1